E78.1

Pure hypertriglyceridemia

Pure hypertriglyceridemia (ICD-10 E78.1) is a lipid disorder characterized by persistently elevated levels of triglycerides in the blood, often occurring independently of significantly raised low-density lipoprotein cholesterol (LDL-C) or total cholesterol. Triglycerides are a type of fat molecule that serves as a major energy source, stored in adipose tissue. While mild to moderate elevations are common and frequently asymptomatic, severe hypertriglyceridemia can pose significant health risks. This condition can be classified as either primary (genetic) or secondary (acquired). Primary hypertriglyceridemia typically results from inherited genetic mutations affecting enzymes or apolipoproteins crucial for triglyceride metabolism, such as lipoprotein lipase (LPL) deficiency or apolipoprotein C-II deficiency, which can lead to extremely high triglyceride levels (e.g., >1000 mg/dL). Familial hypertriglyceridemia, another primary form, usually presents with moderate elevations (250-1000 mg/dL) and is often polygenic. Secondary causes are more prevalent and include a wide array of lifestyle factors, underlying medical conditions, and medications. Key contributors include obesity, uncontrolled diabetes mellitus (particularly type 2), excessive alcohol consumption, and diets rich in refined carbohydrates and saturated or trans fats. Other medical conditions such as hypothyroidism, nephrotic syndrome, and chronic kidney disease can also elevate triglyceride levels. Certain medications, including oral estrogens, corticosteroids, beta-blockers, thiazide diuretics, and some antipsychotics, are known to induce or exacerbate hypertriglyceridemia. Pregnancy can also cause physiological increases in triglycerides. Chronic, severe hypertriglyceridemia is a major risk factor for acute pancreatitis, a serious and potentially life-threatening inflammatory condition of the pancreas. Long-term moderate elevations are also implicated in increasing the risk of cardiovascular disease, especially when combined with other metabolic risk factors.

Clinical Symptoms

  • Usually asymptomatic in mild to moderate cases
  • Abdominal pain (especially in severe cases, indicative of pancreatitis)
  • Nausea
  • Vomiting
  • Eruptive xanthomas (small, yellow-red papules on the skin, often on extensor surfaces)
  • Lipemia retinalis (milky appearance of retinal blood vessels, visible on fundoscopic examination)
  • Hepatomegaly (enlarged liver)
  • Splenomegaly (enlarged spleen)
  • Dyspnea (shortness of breath) in severe cases
  • Fatigue or lethargy

Common Causes

  • Genetic predisposition (e.g., familial hypertriglyceridemia, lipoprotein lipase deficiency, apolipoprotein C-II deficiency)
  • Obesity and metabolic syndrome
  • Uncontrolled diabetes mellitus (especially type 2)
  • Excessive alcohol consumption
  • Diets high in refined carbohydrates, simple sugars, saturated fats, and trans fats
  • Hypothyroidism
  • Kidney disease (e.g., nephrotic syndrome, chronic kidney disease)
  • Certain medications (e.g., oral estrogens, corticosteroids, beta-blockers, thiazide diuretics, some atypical antipsychotics, retinoids)
  • Pregnancy
  • Cushing's syndrome
  • Glycogen storage diseases

Documentation & Coding Tips

Document the specificity and severity of hypertriglyceridemia, including whether it is primary or secondary, and its current control status. Explicitly state if it's 'pure' to distinguish it from mixed dyslipidemia.

Example: Patient is a 55-year-old male presenting for follow-up of **chronic, severe pure hypertriglyceridemia (E78.1)**, currently **uncontrolled** despite high-dose fenofibrate 160mg daily. Recent lab work shows triglycerides 720 mg/dL (target <150 mg/dL). This is considered **primary hypertriglyceridemia** based on early onset, strong family history, and thorough exclusion of secondary causes (normal TSH, controlled A1c, no excessive alcohol use). The patient's severe hypertriglyceridemia significantly elevates his **risk for acute pancreatitis (HCC)** and accelerates **atherosclerotic cardiovascular disease (HCC)**. Discussed patient's adherence to a low-fat diet, which he reports is 'mostly' followed. He has an active diagnosis of **Type 2 Diabetes Mellitus with peripheral neuropathy (E11.40), poorly controlled (HCC)**, and **morbid obesity (E66.3, HCC)**. Plan: Increase fenofibrate to maximum tolerated dose, initiate prescription-strength omega-3 fatty acids (icosapent ethyl), provide comprehensive dietary counseling on very-low-fat diet, and refer to endocrinology for specialized lipid management. Recheck lipids in 6 weeks. This visit involved complex medical decision making due to multiple comorbidities and high risk of complications, supporting CPT 99214.

Billing Focus: Documentation of 'pure' vs. 'mixed', 'chronic', 'severe', 'uncontrolled', 'primary' vs. 'secondary', and specific lab values are crucial for accurate E78.1 coding. Linking to medication management, dietary counseling, and specialist referral justifies medical necessity and higher E&M levels.

Clearly identify and document any secondary causes of hypertriglyceridemia or associated comorbidities, specifying their impact on management.

Example: Patient is a 48-year-old female seen for follow-up. Diagnosed with **pure hypertriglyceridemia (E78.1)**. Current triglycerides 450 mg/dL. This is believed to be **secondary to poorly controlled Type 2 Diabetes Mellitus (E11.9, HCC)**, with an A1c of 9.2%, and also exacerbated by **chronic excessive alcohol use (F10.10, HCC)**, which the patient admits to. Patient also has **essential (primary) hypertension (I10, HCC)**, currently well-controlled on lisinopril. The elevated triglycerides are a direct consequence of her diabetic state and alcohol consumption, contributing to her overall cardiovascular risk profile. Discussed strict glycemic control and complete alcohol cessation as primary interventions for triglyceride reduction. Initiated fenofibrate 145mg daily. Referred to substance abuse counseling. Ordered HBA1c and comprehensive metabolic panel today. Education provided on diet and exercise. This visit reflects management of multiple, interacting chronic conditions with significant lifestyle modification counseling and referral, supporting CPT 99214.

Billing Focus: Documenting 'secondary to' with specific ICD-10 codes (e.g., E11.9 for diabetes, F10.10 for alcohol use) provides critical specificity for billing. Detailing the impact of these secondary causes on the hypertriglyceridemia reinforces medical necessity for treatment and complexity of care.

Document the comprehensive management plan, including lifestyle modifications, pharmacotherapy, and monitoring, with specific details on patient education and adherence.

Example: 34-year-old male with new diagnosis of **pure hypertriglyceridemia (E78.1)**, mild severity (Triglycerides 280 mg/dL). No family history. Etiology appears to be primarily lifestyle-related, with a sedentary lifestyle and diet high in saturated fats and simple carbohydrates contributing to **obesity (E66.9)**. Patient has no other significant comorbidities or associated conditions. Extensive **medical nutrition therapy (CPT 97802, 97803)** provided by certified dietician, focusing on low-glycemic index foods, increased fiber, and reduction of saturated/trans fats. Patient engaged in shared decision-making regarding lifestyle changes and agreed to a 12-week trial of rigorous diet and exercise before considering pharmacotherapy. Education included risks of untreated hypertriglyceridemia (e.g., future cardiovascular risk). Follow-up lipid panel ordered for 3 months. This visit involved detailed patient education and counseling, supporting CPT 99213/99402.

Billing Focus: Documenting specific interventions like 'medical nutrition therapy (CPT 97802, 97803)', detailed patient education, and a '12-week trial of rigorous diet and exercise' supports medical necessity for these services. Specifying the 'mild severity' and 'lifestyle-related' etiology provides context for the non-pharmacological initial approach.

Relevant CPT Codes

Related Diagnoses

Hierarchy